大连医科李华军等:岩藻多糖改善小鼠血脂异常和肠道菌群
  • 分析岩藻多糖对小鼠肠道微生物群和血脂异常的影响;
  • 体外实验表明岩藻多糖可支持3个乳酸菌菌株的生长;
  • 岩藻多糖可降低高脂饮食小鼠的总血清胆固醇、低密度脂蛋白胆固醇和肝脏胆固醇水平,改善肝脏的脂肪变性;
  • 岩藻多糖能够降低肝脏中胆固醇相关蛋白(HMGCR,SREBP-2)的表达;
  • 通过对肠道微生物群的16S rRNA基因序列分析,岩藻多糖增加了拟杆菌门和拟普雷沃菌属的丰度,但减少了厚壁菌门、葡萄球菌属和链球菌属的丰度。
主编推荐语
mildbreeze
大连医科大学李华军团队主导的一项研究,近期在Journal of Functional Foods发表。该研究显示,提取自裙带菜中的岩藻多糖,可改善高脂饮食小鼠的血脂异常、脂肪肝和肠道菌群,或能为治疗相关代谢疾病带来启示。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

Fucoidan alleviates dyslipidemia and modulates gut microbiota in high-fat diet-induced mice

高脂饮食诱导的小鼠中岩藻多糖可以改善血脂异常并调节肠道菌群

10.1016/j.jff.2018.07.006

2018-07-20, Article

Abstract & Authors:展开

Abstract:收起
Fucoidan is a functional food that possesses various biological activities. This study aims to determine the effects of fucoidan from Undaria pinnatifida on gut microbiota and dyslipidemia in BALB/c mice. In vitro, fucoidan could support the growth of three lactic acid bacteria strains. The test groups with high fat diet (HFD) were gavaged with fucoidan at a dose of 50 mg/kg/day or 100 mg/kg/day for 8 weeks. Fucoidan decreased total serum cholesterol (P < 0.05), LDL-C (P < 0.05) and liver cholesterol levels (P < 0.05). The steatosis of liver was improved in fucoidan-supplemented groups. Fucoidan also decreased the expression of cholesterol related proteins (HMGCR, SREBP-2) in liver (P < 0.05). The 16S rRNA gene sequence analysis of gut microbiota showed that fucoidan increased abundance of Bacteroidetes and Alloprevotella, whereas decreased abundance of Firmicutes, Staphylococcus and Streptococcus. Taken together, the results suggest fucoidan alleviates dyslipidemia and modulates gut microbiota in HFD-fed mice.

First Authors:
Min Liu,Lin Ma,Qichao Chen

Correspondence Authors:
Huajun Li

All Authors:
Min Liu,Lin Ma,Qichao Chen,Pengyu Zhang,Chao Chen,Lilin Jia,Huajun Li

评论